The inhibition of Src enhanced the cytotoxicity of cisplatin and paclitaxel in drug-sensitive ovarian cancer cells and restores sensitivity in drug resistant cells, and these effects are dependent on caspase-3 activity [63]. This evidence concerns the gene SRC and ovarian cancer.